

Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Growth 2026-2032

<https://marketpublishers.com/r/GC05AFE8F91EEN.html>

Date: July 2026

Pages: 105

Price: US\$ 3,660.00 (Single User License)

ID: GC05AFE8F91EEN

Abstracts

The global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market size is predicted to grow from US\$ 4738 million in 2025 to US\$ 18506 million in 2032; it is expected to grow at a CAGR of 21.6% from 2026 to 2032.

Non-steroidal androgen receptor inhibitors (NSARIs) are a class of oral small-molecule drugs that competitively bind to the androgen receptor (AR), inhibiting its nuclear translocation and transcriptional activity without possessing a steroidal structure; they selectively block androgen signaling pathways that drive prostate cancer progression and represent a core component of endocrine therapy for prostate cancer; the class has evolved from first-generation agents (e.g., bicalutamide) to second-generation high-affinity inhibitors such as Enzalutamide, Apalutamide, and Darolutamide, with continuous improvements in efficacy, resistance management, and safety profile, primarily indicated for nmCRPC and mHSPC and typically used in combination with androgen deprivation therapy (ADT). The global market for non-steroidal androgen receptor inhibitors is estimated at USD 4.8 billion in 2025, with a projected CAGR of approximately 20.85% from 2025 to 2030, corresponding to an annual treated patient population of about 500,000?600,000, driven by increasing penetration in nmCRPC, mCRPC, and mHSPC. Nominal capacity from the global high-potency small-molecule API network is sufficient to meet demand, and capacity does not constitute a constraint. Average treatment cost per patient per year is approximately USD 90,000?100,000 in the U.S., USD 50,000?70,000 in Europe, and USD 15,000?20,000 in China post-reimbursement negotiations, resulting in a weighted average of about USD 65,000 per patient per year, with a blended gross margin of roughly 85?90%.

Downstream demand is concentrated in the prostate cancer treatment pathway within oncology (nmCRPC ? mCRPC ? mHSPC). The value chain upstream consists of high-

potency APIs and key intermediates synthesized via multi-step heterocyclic processes; midstream commercialization is led by originator companies (Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, and Bayer AG/Orion Corporation); downstream channels consist of hospitals and oncology specialty clinics. The global industry structure is characterized by ?originator oligopoly + guideline-driven adoption + patent protection,? with primary competition from Enzalutamide, Apalutamide, and Darolutamide. The core compound patent of Darolutamide is expected to expire around 2030, but indication, formulation, and regional patent extensions may prolong actual market exclusivity to 2032?2035. Overall, the market is in the late growth stage, driven primarily by indication expansion and an increasing aging patient population, with key uncertainty arising from post-patent generic entry and reimbursement pressure.

LP Information, Inc. (LPI) ' newest research report, the ?Non-steroidal Androgen Receptor Inhibitors?NSARIs? Industry Forecast? looks at past sales and reviews total world Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales for 2026 through 2032. With Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Non-steroidal Androgen Receptor Inhibitors?NSARIs? industry.

This Insight Report provides a comprehensive analysis of the global Non-steroidal Androgen Receptor Inhibitors?NSARIs? landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-steroidal Androgen Receptor Inhibitors?NSARIs? portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-steroidal Androgen Receptor Inhibitors?NSARIs? and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-steroidal Androgen Receptor Inhibitors?NSARIs?.

This report presents a comprehensive overview, market shares, and growth

opportunities of Non-steroidal Androgen Receptor Inhibitors?NSARIs? market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Enzalutamide

Apalutamide

Darolutamide

Bicalutamide

Nilutamide

Segmentation by Molecular:

High BBB Penetration

Low BBB Penetration

Segmentation by Application:

nmCRPC

mCRPC

mHSPC

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Astellas Pharma

Pfizer

Johnson & Johnson

Bayer AG

Orion

Lonza Group

Catalent

WuXi AppTec

Asymchem Laboratories

Recipharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market?

What factors are driving Non-steroidal Androgen Receptor Inhibitors?NSARIs? market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Non-steroidal Androgen Receptor Inhibitors?NSARIs? market opportunities

vary by end market size?

How does Non-steroidal Androgen Receptor Inhibitors?NSARIs? break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country/Region, 2021, 2025 & 2032

2.2 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Type

2.2.1 Enzalutamide

2.2.2 Apalutamide

2.2.3 Darolutamide

2.2.4 Bicalutamide

2.2.5 Nilutamide

2.2.6 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type

2.2.6.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)

2.2.6.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Type (2021-2026)

2.2.6.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Type (2021-2026)

2.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Molecular

2.3.1 High BBB Penetration

2.3.2 Low BBB Penetration

2.3.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Molecular

2.3.3.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular (2021-2026)

2.3.3.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Molecular (2021-2026)

2.3.3.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Molecular (2021-2026)

2.4 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Application

2.4.1 nmCRPC

2.4.2 mCRPC

2.4.3 mHSPC

2.4.4 Others

2.4.5 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application

2.4.5.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2021-2026)

2.4.5.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Application (2021-2026)

2.4.5.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Breakdown Data by Company

3.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Company (2021-2026)

3.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company (2021-2026)

3.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Company (2021-2026)

3.2.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company (2021-2026)

3.2.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company (2021-2026)

3.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Company

3.4 Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Location Distribution

- 3.4.2 Players Non-steroidal Androgen Receptor Inhibitors?NSARIs? Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR NON-STEROIDAL ANDROGEN RECEPTOR INHIBITORS?NSARIS? BY GEOGRAPHIC REGION

- 4.1 World Historic Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size by Geographic Region (2021-2026)
 - 4.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Geographic Region (2021-2026)
 - 4.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
- 4.4 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
- 4.5 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
- 4.6 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth

5 AMERICAS

- 5.1 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country
 - 5.1.1 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
 - 5.1.2 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
- 5.2 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
- 5.3 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region

6.1.1 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region
(2021-2026)

6.1.2 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by
Region (2021-2026)

6.2 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type
(2021-2026)

6.3 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country

7.1.1 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country
(2021-2026)

7.1.2 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by
Country (2021-2026)

7.2 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type
(2021-2026)

7.3 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country

8.1.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)

8.1.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)

8.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)

8.3 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

10.3 Manufacturing Process Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

10.4 Industry Chain Structure of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

- 11.1.2 Indirect Channels
- 11.2 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Distributors
- 11.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Customer

12 WORLD FORECAST REVIEW FOR NON-STEROIDAL ANDROGEN RECEPTOR INHIBITORS?NSARIS? BY GEOGRAPHIC REGION

- 12.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size Forecast by Region
 - 12.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Region (2027-2032)
 - 12.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Type (2027-2032)
- 12.7 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 Astellas Pharma
 - 13.1.1 Astellas Pharma Company Information
 - 13.1.2 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.1.3 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 Astellas Pharma Main Business Overview
 - 13.1.5 Astellas Pharma Latest Developments
- 13.2 Pfizer
 - 13.2.1 Pfizer Company Information
 - 13.2.2 Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.2.3 Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Pfizer Main Business Overview

- 13.2.5 Pfizer Latest Developments
- 13.3 Johnson & Johnson
 - 13.3.1 Johnson & Johnson Company Information
 - 13.3.2 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.3.3 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Johnson & Johnson Main Business Overview
 - 13.3.5 Johnson & Johnson Latest Developments
- 13.4 Bayer AG
 - 13.4.1 Bayer AG Company Information
 - 13.4.2 Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.4.3 Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Bayer AG Main Business Overview
 - 13.4.5 Bayer AG Latest Developments
- 13.5 Orion
 - 13.5.1 Orion Company Information
 - 13.5.2 Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.5.3 Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Orion Main Business Overview
 - 13.5.5 Orion Latest Developments
- 13.6 Lonza Group
 - 13.6.1 Lonza Group Company Information
 - 13.6.2 Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.6.3 Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Lonza Group Main Business Overview
 - 13.6.5 Lonza Group Latest Developments
- 13.7 Catalent
 - 13.7.1 Catalent Company Information
 - 13.7.2 Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.7.3 Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.7.4 Catalent Main Business Overview
- 13.7.5 Catalent Latest Developments
- 13.8 WuXi AppTec
 - 13.8.1 WuXi AppTec Company Information
 - 13.8.2 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.8.3 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 WuXi AppTec Main Business Overview
 - 13.8.5 WuXi AppTec Latest Developments
- 13.9 Asymchem Laboratories
 - 13.9.1 Asymchem Laboratories Company Information
 - 13.9.2 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.9.3 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Asymchem Laboratories Main Business Overview
 - 13.9.5 Asymchem Laboratories Latest Developments
- 13.10 Recipharm
 - 13.10.1 Recipharm Company Information
 - 13.10.2 Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
 - 13.10.3 Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 Recipharm Main Business Overview
 - 13.10.5 Recipharm Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Enzalutamide

Table 4. Major Players of Apalutamide

Table 5. Major Players of Darolutamide

Table 6. Major Players of Bicalutamide

Table 7. Major Players of Nilutamide

Table 8. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)

Table 9. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)

Table 10. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Type (2021-2026) & (\$ million)

Table 11. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Type (2021-2026)

Table 12. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Type (2021-2026) & (US\$/Ton)

Table 13. Major Players of High BBB Penetration

Table 14. Major Players of Low BBB Penetration

Table 15. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Molecular (2021-2026) & (Tons)

Table 16. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular (2021-2026)

Table 17. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Molecular (2021-2026) & (\$ million)

Table 18. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Molecular (2021-2026)

Table 19. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Molecular (2021-2026) & (US\$/Ton)

Table 20. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale by Application (2021-2026) & (Tons)

Table 21. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2021-2026)

Table 22. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Application (2021-2026) & (\$ million)

Table 23. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Application (2021-2026)

Table 24. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Application (2021-2026) & (US\$/Ton)

Table 25. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Company (2021-2026) & (Tons)

Table 26. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company (2021-2026)

Table 27. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company (2021-2026) & (\$ millions)

Table 28. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company (2021-2026)

Table 29. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Company (2021-2026) & (US\$/Ton)

Table 30. Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Producing Area Distribution and Sales Area

Table 31. Players Non-steroidal Androgen Receptor Inhibitors?NSARIs? Products Offered

Table 32. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 33. New Products and Potential Entrants

Table 34. Market M&A Activity & Strategy

Table 35. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Geographic Region (2021-2026) & (Tons)

Table 36. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Geographic Region (2021-2026)

Table 37. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 38. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Geographic Region (2021-2026)

Table 39. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country/Region (2021-2026) & (Tons)

Table 40. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2021-2026)

Table 41. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country/Region (2021-2026) & (\$ millions)

Table 42. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue

Market Share by Country/Region (2021-2026)

Table 43. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)

Table 44. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country (2021-2026)

Table 45. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026) & (\$ millions)

Table 46. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)

Table 47. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)

Table 48. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region (2021-2026) & (Tons)

Table 49. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Region (2021-2026)

Table 50. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Region (2021-2026) & (\$ millions)

Table 51. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)

Table 52. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)

Table 53. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)

Table 54. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026) & (\$ millions)

Table 55. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)

Table 56. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)

Table 57. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)

Table 58. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)

Table 59. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)

Table 60. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)

Table 61. Key Market Drivers & Growth Opportunities of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Table 62. Key Market Challenges & Risks of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Table 63. Key Industry Trends of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Table 64. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Raw Material

Table 65. Key Suppliers of Raw Materials

Table 66. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Distributors List

Table 67. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Customer List

Table 68. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Region (2027-2032) & (Tons)

Table 69. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 70. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)

Table 71. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 72. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Region (2027-2032) & (Tons)

Table 73. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 74. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)

Table 75. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 76. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)

Table 77. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 78. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Type (2027-2032) & (Tons)

Table 79. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 80. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Application (2027-2032) & (Tons)

Table 81. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 82. Astellas Pharma Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 83. Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 84. Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 85. Astellas Pharma Main Business

Table 86. Astellas Pharma Latest Developments

Table 87. Pfizer Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 88. Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 89. Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 90. Pfizer Main Business

Table 91. Pfizer Latest Developments

Table 92. Johnson & Johnson Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 93. Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 94. Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 95. Johnson & Johnson Main Business

Table 96. Johnson & Johnson Latest Developments

Table 97. Bayer AG Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 98. Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 99. Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 100. Bayer AG Main Business

Table 101. Bayer AG Latest Developments

Table 102. Orion Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 103. Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 104. Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 105. Orion Main Business

Table 106. Orion Latest Developments

Table 107. Lonza Group Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 108. Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product

Portfolios and Specifications

Table 109. Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 110. Lonza Group Main Business

Table 111. Lonza Group Latest Developments

Table 112. Catalent Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 113. Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 114. Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 115. Catalent Main Business

Table 116. Catalent Latest Developments

Table 117. WuXi AppTec Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 118. WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 119. WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 120. WuXi AppTec Main Business

Table 121. WuXi AppTec Latest Developments

Table 122. Asymchem Laboratories Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 123. Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 124. Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 125. Asymchem Laboratories Main Business

Table 126. Asymchem Laboratories Latest Developments

Table 127. Recipharm Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors

Table 128. Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications

Table 129. Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 130. Recipharm Main Business

Table 131. Recipharm Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Figure 2. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth Rate 2021-2032 (Tons)

Figure 7. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2025)

Figure 10. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Enzalutamide

Figure 12. Product Picture of Apalutamide

Figure 13. Product Picture of Darolutamide

Figure 14. Product Picture of Bicalutamide

Figure 15. Product Picture of Nilutamide

Figure 16. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type in 2026

Figure 17. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Type (2021-2026)

Figure 18. Product Picture of High BBB Penetration

Figure 19. Product Picture of Low BBB Penetration

Figure 20. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular in 2026

Figure 21. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Molecular (2021-2026)

Figure 22. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in nmCRPC

Figure 23. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: nmCRPC (2021-2026) & (Tons)

Figure 24. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in mCRPC

Figure 25. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market:
mCRPC (2021-2026) & (Tons)

Figure 26. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in mHSPC

Figure 27. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market:
mHSPC (2021-2026) & (Tons)

Figure 28. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in Others

Figure 29. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: Others
(2021-2026) & (Tons)

Figure 30. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market
Share by Application (2025)

Figure 31. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue
Market Share by Application in 2025

Figure 32. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Company in
2025 (Tons)

Figure 33. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market
Share by Company in 2025

Figure 34. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company
in 2025 (\$ millions)

Figure 35. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue
Market Share by Company in 2025

Figure 36. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market
Share by Geographic Region (2021-2026)

Figure 37. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue
Market Share by Geographic Region in 2025

Figure 38. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales
2021-2026 (Tons)

Figure 39. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue
2021-2026 (\$ millions)

Figure 40. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales
2021-2026 (Tons)

Figure 41. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue
2021-2026 (\$ millions)

Figure 42. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales
2021-2026 (Tons)

Figure 43. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue
2021-2026 (\$ millions)

Figure 44. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Sales 2021-2026 (Tons)

Figure 45. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 (\$ millions)

Figure 46. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country in 2025

Figure 47. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)

Figure 48. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)

Figure 49. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)

Figure 50. United States Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 51. Canada Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 52. Mexico Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 53. Brazil Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 54. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Region in 2025

Figure 55. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Region (2021-2026)

Figure 56. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)

Figure 57. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)

Figure 58. China Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 59. Japan Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 60. South Korea Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 61. Southeast Asia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 62. India Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 63. Australia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 64. China Taiwan Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Revenue Growth 2021-2026 (\$ millions)

Figure 65. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country in 2025

Figure 66. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)

Figure 67. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)

Figure 68. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)

Figure 69. Germany Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 70. France Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 71. UK Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 72. Italy Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 73. Russia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 74. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country (2021-2026)

Figure 75. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)

Figure 76. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)

Figure 77. Egypt Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 78. South Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 79. Israel Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 80. Turkey Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 81. GCC Countries Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 (\$ millions)

Figure 82. Manufacturing Cost Structure Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs? in 2026

Figure 83. Manufacturing Process Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Figure 84. Industry Chain Structure of Non-steroidal Androgen Receptor Inhibitors?NSARIs?

Figure 85. Channels of Distribution

Figure 86. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Forecast by Region (2027-2032)

Figure 87. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Region (2027-2032)

Figure 88. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Forecast by Type (2027-2032)

Figure 89. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Type (2027-2032)

Figure 90. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Forecast by Application (2027-2032)

Figure 91. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GC05AFE8F91EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC05AFE8F91EEN.html>